
    
      OBJECTIVES:

        -  To assess the therapeutic activity of a mitomycin C and ifosfamide combination, in terms
           of progression-free survival rate at 6 months, in patients with metastatic stage IV
           adenocarcinoma of the pancreas.

      OUTLINE: Patients receive mitomycin C IV on day 1 and ifosfamide IV on days 1-3. Courses
      repeat every 4 weeks for up to 6 courses in the absence of disease progression or
      unacceptable toxicity.
    
  